|  |  |  |  |  |
| Company | Aladdin Scientific Corporation | Aladdin Scientific Corporation | Aladdin Scientific Corporation | Aladdin Scientific Corporation | Aladdin Scientific Corporation |
| Item | CKB Human Pre-designed siRNA Set A | Dezamizumab (anti-Serum Amyloid P) | Glukagon (19-29) (human),TFA | IRE1α kinase-IN-2 | Recombinant Mouse CXCL1/KC Protein |
| Catalog Number | C1480769 | Ab175509 | G321154 | I648023 | rp168795 |
| Price | Supplier Page | Supplier Page | Supplier Page | Supplier Page | Supplier Page |
| Quantity | 1Set | 100µg, 5mg, 1mg, 10mg | 250mg, 5mg, 50mg, 10mg, 25mg | 100mg, 5mg, 50mg, 10mg, 25mg | 100µg, 10µg, 50µg, 1mg |
| Type | Bioactive Small Molecules | Chelating Agents & Ligands | Chelating Agents & Ligands | Chelating Agents & Ligands | Chelating Agents & Ligands |
| Description | CKB Human Pre-designed siRNA Set A contains three designed siRNAs for CKB gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control. Components CKB siRNA-1: 5 nmol (HPLC) CKB siRNA-2: 5 nmol (HPLC) CKB siRNA-3: 5 nmol (HPLC) siRNA Negative Control: 5 nmol (CKB Human Pre-designed siRNA Set A contains three designed siRNAs for CKB gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control. Components CKB siRNA-1: 5 nmol (HPLC) CKB siRNA-2: 5 nmol (HPLC) CKB siRNA-3: 5 nmol (HPLC) siRNA Negative Control: 5 nmol (HPLC) FAM-labeled siRNA Negative Control: 5 nmol (HPLC) GAPDH siRNA Positive Control:5 nmol (HPLC)... Read More | Dezamizumab (anti-Serum Amyloid P) is a fully humanized recombinant monoclonal IgG1 anti-serum amyloid P component (SAP) antibody, with potential anti-amyloid activity. Dezamizumab (anti-Serum Amyloid P) triggers immunotherapeutic clearance of amyloid. Dezamizumab (anti-Serum Amyloid P) can be used Dezamizumab (anti-Serum Amyloid P) is a fully humanized recombinant monoclonal IgG1 anti-serum amyloid P component (SAP) antibody, with potential anti-amyloid activity. Dezamizumab (anti-Serum Amyloid P) triggers immunotherapeutic clearance of amyloid. Dezamizumab (anti-Serum Amyloid P) can be used in research of Amyloid light-chain (AL) amyloidosis... Read More | Inquire | IRE1α kinase-IN-2 is a potent IRE1α kinase inhibitor, with an EC 50 of 0.82 µM. IRE1α kinase-IN-2 inhibits IRE1α kinase autophosphorylation (IC 50 =3.12 µM). IRE1α kinase-IN-2 inhibits XBP1 mRNA splicing in the WT cell lines.In VitroIRE1α kinase-IN-2 (compoundIRE1α kinase-IN-2 is a potent IRE1α kinase inhibitor, with an EC 50 of 0.82 µM. IRE1α kinase-IN-2 inhibits IRE1α kinase autophosphorylation (IC 50 =3.12 µM). IRE1α kinase-IN-2 inhibits XBP1 mRNA splicing in the WT cell lines.In VitroIRE1α kinase-IN-2 (compound 3) inhibits XBP1 mRNA splicing, even during ER stress. MCE has not independently confirmed the accuracy of these methods. They are for reference only.Form:Solid... Read More | Purity>97% by SDS-PAGE and HPLC analyses.Additional sequence informationFunction N-terminal glycine. Full-length mature chain lacking the signal peptideFunctionHas chemotactic activity for neutrophils. May play a role in inflammation and exerts its effects on endothelial cells in an autocrine Purity>97% by SDS-PAGE and HPLC analyses.Additional sequence informationFunction N-terminal glycine. Full-length mature chain lacking the signal peptideFunctionHas chemotactic activity for neutrophils. May play a role in inflammation and exerts its effects on endothelial cells in an autocrine fashion. In vitro, the processed forms GRO-alpha(4-73), GRO-alpha(5-73) and GRO-alpha(6-73) show a 30-fold higher chemotactic activity.Post-translationalN-terminal processed forms GRO-alpha(4-73), GRO-alpha(5-73) and GRO-alpha(6-73) are produced by proteolytic cleavage after secretion from peripheral blood monocytes... Read More |
| Get Quote | Supplier Page | Supplier Page | Supplier Page | Supplier Page | Supplier Page |